Developer docs
API playgroundTry for free, no card

Search company profiles

NDA Partners

Full company profile

uuid000hmvz

Namestring
NDA Partners
Legal namestring
NDA Partners LLC
Websiteurl
ndapartners.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

NDA Partners LLC is a life sciences management consulting firm founded in 2013 and headquartered in Washington, DC. The firm provides high-value expert advisory services to pharmaceutical, biotechnology, and medical device companies worldwide, supporting the product development life cycle from initial concept through marketing authorization. Its services include product development and regulatory strategy, development program planning and management, expert scientific and technical advice, biostatistics, market access and reimbursement, pediatric development, quality management systems, and litigation support/expert witness services for law firms. The firm operates through six organized Practice Areas: Biologics Development, Medical Device Development, Drug Development, Generics Product Development, Product Quality & CMC Services, and Quantitative Drug Development Strategies. NDA Partners also assembles custom Product Development Teams (PDTs) that design, plan, and manage regulatory and product development programs on behalf of early-stage biopharma and device clients.

The firm's core technology is its curated network of top-tier Expert Consultants — including three former FDA Center Directors, the former CEO/CSO of the United States Pharmacopeial Convention (USP), more than 30 former senior-level regulatory agency executives, and dozens of former pharmaceutical industry senior executives — combined with full-spectrum functional expertise across regulatory, nonclinical, CMC, clinical, and quality domains. This expert network is the platform on which engagements are delivered rather than a software product.

Revenue is generated through professional services engagements priced on a quote basis, with multi-year contracts typical. Customers include global pharmaceutical companies, emerging biopharma, medical device companies, national and global law firms, and private investment firms in the life sciences space. As of 2023, NDA Partners operates as a ProPharma company, having joined ProPharma to scale its consultant base and broaden its service offerings across regulatory sciences, clinical research solutions, life science consulting, pharmacovigilance, and medical information services.

Short descriptiontext

NDA Partners is a life sciences management consulting firm providing expert regulatory and product development advisory services to global pharmaceutical, biotechnology, and medical device companies, leveraging a network of former FDA and industry executives; since 2023 it operates as a ProPharma company.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersWashington, United States
HQ citystring
Washington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regulatory affairs consulting, clinical development consulting, biopharmaceutical consulting, medical device consulting, product development strategy
Industry2 codes
PRIMARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAKAI
Clinical Quality Assurance (GCP QA, TMF/QMS oversight)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
NAICS code2 codes
  • Management Consulting Services54161
  • Other Scientific and Technical Consulting Services541690
SIC code1 code
  • Services-Management Consulting Services8742
Product category
Life Sciences Consulting
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Expert Advisory Services
TypeProfessional Services
Description

High-value advisory services through Expert Consultants supporting product development life cycle from initial concept to marketing authorization. Includes product development and regulatory strategy, development program planning and management, and expert scientific and technical advice.

ndapartners.com
2Development Teams
TypeProfessional Services
Description

Formation of world-class product development teams (PDTs) for early-stage biopharma and medical device companies that design, plan, and manage regulatory and product development programs.

ndapartners.com
3Specialized Service Offerings
TypeProfessional Services
Description

Biostatistics, market access and reimbursement, pediatrics, and quality management systems consulting services.

ndapartners.com
4Expert Witness Services
TypeProfessional Services
Description

Litigation support services for law firms including expert reports, depositions, and trial testimony for cases involving antitrust violations, patent infringement, product liability, and supply chain failures.

ndapartners.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Technology or R&D
Pricing details1 tier
1Custom consulting engagements
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based pricing; contact info@NDApartners.com or 540-738-2550 to discuss requirements

ndapartners.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

NDA Partners provides high-value expert consulting services to pharmaceutical, biotechnology, and medical device companies worldwide, covering the full product development life cycle from initial concept through marketing authorization. Core offerings include Expert Advisory Services on regulatory strategy, Product Development Teams (PDTs) that design and manage development programs, and specialized services in biostatistics, market access, pediatrics, quality management systems, and expert witness support for litigation. The firm assigns top-tier Expert Consultants, including former FDA Center Directors and senior industry executives, on every engagement.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

NDA Partners is a life sciences management consulting organization offering a comprehensive suite of expert consulting services rather than a unified software product. The firm provides Expert Advisory Services, Development Teams (PDTs), and Specialized Service Offerings organized across six Practice Areas: Biologics Development, Medical Device Development, Drug Development, Generics Product Development, Product Quality & CMC Services, and Quantitative Drug Development Strategies. Services span regulatory strategy, biostatistics, market access, pediatrics, quality management systems, and expert witness support. The company recently joined ProPharma, expanding its capabilities in regulatory sciences, clinical research solutions, and pharmacovigilance services.

Product and service13 records
1Expert Advisory Services
CategoryCore consulting service
Description

High-value advisory services delivered through top-tier Expert Consultants supporting the product development life cycle from initial concept to marketing authorization, including product development and regulatory strategy, development program planning and management, and expert scientific and technical advice, for pharmaceutical, biotechnology, and medical device clients.

2Product Development Teams (PDTs)
CategoryCore consulting service
Description

Formation of world-class product development teams that design, plan, and manage regulatory and product development programs for inventors, IP owners, and early-stage biopharma and medical device companies.

3Biostatistics Services
CategorySpecialized service
Description

Traditional and advanced statistical expertise for companies developing medical products, including adaptive trial design, Bayesian statistics, and Model-Informed Drug Development.

4Market Access and Reimbursement Services
CategorySpecialized service
Description

Market access landscape assessments, coding strategy development, and payer dossier preparation for new drugs, biologics, devices, and combination products.

5Pediatrics Services
CategorySpecialized service
Description

Comprehensive services for pediatric patient development and registration, including pediatric study design, Pediatric Study Plans, and Rare Pediatric Disease Vouchers.

6Quality Management Systems & Quality System Regulation Services
CategorySpecialized service
Description

Design, implementation, and management of quality and risk management systems, cGMP and cGCP audits, and compliance with ISO 13485 and 21CFR820.

7Expert Witness Services
CategorySpecialized service
Description

Litigation support services for law firms including expert reports, depositions, and trial testimony in cases involving antitrust violations, patent infringement, product liability, and supply chain failures.

8Biologics Development Practice
CategoryPractice area
Description

Expert guidance and support for development of large molecules from initial concept to BLA/MAA/351(k) submission, covering viruses, bacteria, therapeutic serum, toxins, vaccines, blood products, cell and gene therapies, and monoclonal antibodies.

9Medical Device Development Practice
CategoryPractice area
Description

Services facilitating development of novel devices including medical equipment, implants, in vitro and imaging diagnostics, mobile and analytical software devices, and combination products.

10Drug Development Practice
CategoryPractice area
Description

Support across the product development life cycle for new chemical entities, including integrated product development strategy, clinical study design, and regulatory submissions.

11Generics Product Development Practice
CategoryPractice area
Description

Services facilitating development and registration of generic products including ANDA 505(j), 351(k), and 505(b)(2) regulatory pathways.

12Product Quality & CMC Services Practice
CategoryPractice area
Description

Focused on requirements for chemically synthesized molecules for 505(b)(1) and 505(b)(2) applications, including biopharmaceutics, microbiology, compliance, and CMC development strategies.

13Quantitative Drug Development Strategies (QDDS) Practice
CategoryPractice area
Description

State-of-the-art quantitative methodologies including quantitative clinical pharmacology, PKPD and PBPK modeling, clinical simulation, and adaptive trial designs.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

NDA Partners has joined ProPharma, expanding their team of Expert Consultants and service offerings. Together they elevate services as a leading global provider of regulatory sciences, clinical research solutions, life science consulting, pharmacovigilance, and medical information services. NDA Partners is now a ProPharma company, offering expanded capabilities to clients worldwide.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global regulatory affairs, pharmacovigilance, and development consulting firm with deep FDA/EMA expertise serving pharma and biotech. Comparable regulatory services portfolio, scaled larger via acquisitions.

TypeDirect peer
Description

Parent organization of NDA Partners since 2023; provides regulatory sciences, clinical research solutions, pharmacovigilance, and life science consulting globally. Direct overlap in regulatory consulting for pharma, biotech, and medical device clients.

3Camargo Pharmaceutical Services
TypeDirect peer
Description

Boutique regulatory and drug development consultancy serving emerging and mid-size pharma with 505(b)(2), ANDA, and full development pathway services. Closely comparable in niche positioning and small-firm, expert-led delivery model.

TypeDirect peer
Description

Specialty regulatory consulting firm staffed largely by former FDA reviewers and industry experts, focused on biologics, cell and gene therapies, and related CMC/regulatory submissions. Comparable expert-network model and FDA alumni bench.

TypeBroad incumbent
Description

Major global CRO providing clinical, regulatory, and consulting services to pharma, biotech, and medical device companies. Overlaps with NDA Partners in regulatory strategy and development consulting at a much larger scale.

TypeDirect peer
Description

Regulatory and scientific consulting firm supporting medical device, pharmaceutical, and combination product companies with FDA strategy, submissions, and quality compliance. Comparable in regulatory advisory focus and mid-size boutique scale.

TypeBroad incumbent
Description

Global CRO/preclinical services provider with regulatory and development consulting capabilities supporting pharma and biotech product development. Adjacent but broader in scope, with overlapping regulatory consulting offerings.

TypeDirect peer
Description

Mid-size CRO with strong regulatory, clinical development, and product strategy consulting for pharma and biotech, including rare disease and biologics. Comparable in regulatory and development program support with a smaller, expert-led footprint.

TypeBroad incumbent
Description

Largest global CRO with extensive regulatory affairs, R&D consulting, and product development services for life sciences companies. Competes for the same large-pharma and emerging-biotech clients at a different scale.

TypeBroad incumbent
Description

Large global CRO offering regulatory strategy, clinical development, and product development consulting across pharma, biotech, and medical devices. Overlaps with NDA Partners on regulatory advisory but serves a much broader portfolio.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses2 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NDA Partners

Life Sciences Consultingndapartners.com

NDA Partners is a life sciences management consulting firm providing expert regulatory and product development advisory services to global pharmaceutical, biotechnology, and medical device companies, leveraging a network of former FDA and industry executives; since 2023 it operates as a ProPharma company.

What NDA Partners does

NDA Partners LLC is a life sciences management consulting firm founded in 2013 and headquartered in Washington, DC. The firm provides high-value expert advisory services to pharmaceutical, biotechnology, and medical device companies worldwide, supporting the product development life cycle from initial concept through marketing authorization. Its services include product development and regulatory strategy, development program planning and management, expert scientific and technical advice, biostatistics, market access and reimbursement, pediatric development, quality management systems, and litigation support/expert witness services for law firms. The firm operates through six organized Practice Areas: Biologics Development, Medical Device Development, Drug Development, Generics Product Development, Product Quality & CMC Services, and Quantitative Drug Development Strategies. NDA Partners also assembles custom Product Development Teams (PDTs) that design, plan, and manage regulatory and product development programs on behalf of early-stage biopharma and device clients.

The firm's core technology is its curated network of top-tier Expert Consultants — including three former FDA Center Directors, the former CEO/CSO of the United States Pharmacopeial Convention (USP), more than 30 former senior-level regulatory agency executives, and dozens of former pharmaceutical industry senior executives — combined with full-spectrum functional expertise across regulatory, nonclinical, CMC, clinical, and quality domains. This expert network is the platform on which engagements are delivered rather than a software product.

Revenue is generated through professional services engagements priced on a quote basis, with multi-year contracts typical. Customers include global pharmaceutical companies, emerging biopharma, medical device companies, national and global law firms, and private investment firms in the life sciences space. As of 2023, NDA Partners operates as a ProPharma company, having joined ProPharma to scale its consultant base and broaden its service offerings across regulatory sciences, clinical research solutions, life science consulting, pharmacovigilance, and medical information services.

NDA Partners firmographics

Firmographics
Name
NDA Partners
Legal name
NDA Partners LLC
Website
https://ndapartners.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
51–100 employees
Short description
NDA Partners is a life sciences management consulting firm providing expert regulatory and product development advisory services to global pharmaceutical, biotechnology, and medical device companies, leveraging a network of former FDA and industry executives; since 2023 it operates as a ProPharma company.
Ownership category
akta.pro rank

NDA Partners industry classification

Industry
Product category
Life Sciences Consulting
NAICS
Management Consulting Services (54161), Other Scientific and Technical Consulting Services (541690)
SIC
Services-Management Consulting Services (8742)
akta.pro industry
PRIMARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAKAI
Clinical Quality Assurance (GCP QA, TMF/QMS oversight)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)

Keywords

  • Regulatory affairs consulting
  • Clinical development consulting
  • Biopharmaceutical consulting
  • Medical device consulting
  • Product development strategy

Where NDA Partners is headquartered

Location

Headquarters

HQ city
Washington
HQ country
United States
HQ region
North America

Offices1 record

Markets served

NDA Partners business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

  1. Expert Advisory Services: High-value advisory services through Expert Consultants supporting product development life cycle from initial concept to marketing authorization. Includes product development and regulatory strategy, development program planning and management, and expert scientific and technical advice.
  2. Development Teams: Formation of world-class product development teams (PDTs) for early-stage biopharma and medical device companies that design, plan, and manage regulatory and product development programs.
  3. Specialized Service Offerings: Biostatistics, market access and reimbursement, pediatrics, and quality management systems consulting services.
  4. Expert Witness Services: Litigation support services for law firms including expert reports, depositions, and trial testimony for cases involving antitrust violations, patent infringement, product liability, and supply chain failures.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom consulting engagements

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

NDA Partners product offering

Product offering

Core offering

NDA Partners provides high-value expert consulting services to pharmaceutical, biotechnology, and medical device companies worldwide, covering the full product development life cycle from initial concept through marketing authorization. Core offerings include Expert Advisory Services on regulatory strategy, Product Development Teams (PDTs) that design and manage development programs, and specialized services in biostatistics, market access, pediatrics, quality management systems, and expert witness support for litigation. The firm assigns top-tier Expert Consultants, including former FDA Center Directors and senior industry executives, on every engagement.

Product overview

NDA Partners is a life sciences management consulting organization offering a comprehensive suite of expert consulting services rather than a unified software product. The firm provides Expert Advisory Services, Development Teams (PDTs), and Specialized Service Offerings organized across six Practice Areas: Biologics Development, Medical Device Development, Drug Development, Generics Product Development, Product Quality & CMC Services, and Quantitative Drug Development Strategies. Services span regulatory strategy, biostatistics, market access, pediatrics, quality management systems, and expert witness support. The company recently joined ProPharma, expanding its capabilities in regulatory sciences, clinical research solutions, and pharmacovigilance services.

Differentiator

Problem solved

Functional benefit

Products and services

  • Expert Advisory Services High-value advisory services delivered through top-tier Expert Consultants supporting the product development life cycle from initial concept to marketing authorization, including product development and regulatory strategy, development program planning and management, and expert scientific and technical advice, for pharmaceutical, biotechnology, and medical device clients.
  • Product Development Teams (PDTs) Formation of world-class product development teams that design, plan, and manage regulatory and product development programs for inventors, IP owners, and early-stage biopharma and medical device companies.
  • Biostatistics Services Traditional and advanced statistical expertise for companies developing medical products, including adaptive trial design, Bayesian statistics, and Model-Informed Drug Development.
  • Market Access and Reimbursement Services Market access landscape assessments, coding strategy development, and payer dossier preparation for new drugs, biologics, devices, and combination products.
  • Pediatrics Services Comprehensive services for pediatric patient development and registration, including pediatric study design, Pediatric Study Plans, and Rare Pediatric Disease Vouchers.
  • Quality Management Systems & Quality System Regulation Services Design, implementation, and management of quality and risk management systems, cGMP and cGCP audits, and compliance with ISO 13485 and 21CFR820.
  • Expert Witness Services Litigation support services for law firms including expert reports, depositions, and trial testimony in cases involving antitrust violations, patent infringement, product liability, and supply chain failures.
  • Biologics Development Practice Expert guidance and support for development of large molecules from initial concept to BLA/MAA/351(k) submission, covering viruses, bacteria, therapeutic serum, toxins, vaccines, blood products, cell and gene therapies, and monoclonal antibodies.
  • Medical Device Development Practice Services facilitating development of novel devices including medical equipment, implants, in vitro and imaging diagnostics, mobile and analytical software devices, and combination products.
  • Drug Development Practice Support across the product development life cycle for new chemical entities, including integrated product development strategy, clinical study design, and regulatory submissions.
  • Generics Product Development Practice Services facilitating development and registration of generic products including ANDA 505(j), 351(k), and 505(b)(2) regulatory pathways.
  • Product Quality & CMC Services Practice Focused on requirements for chemically synthesized molecules for 505(b)(1) and 505(b)(2) applications, including biopharmaceutics, microbiology, compliance, and CMC development strategies.
  • Quantitative Drug Development Strategies (QDDS) Practice State-of-the-art quantitative methodologies including quantitative clinical pharmacology, PKPD and PBPK modeling, clinical simulation, and adaptive trial designs.

Companies that use NDA Partners

Customer profile

Named customers5 records

Segments5 records

Ideal customer profiles5 records

NDA Partners technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

NDA Partners partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • ProPharmacoreStrategic or Co-development PartnerNDA Partners has joined ProPharma, expanding their team of Expert Consultants and service offerings. Together they elevate services as a leading global provider of regulatory sciences, clinical research solutions, life science consulting, pharmacovigilance, and medical information services. NDA Partners is now a ProPharma company, offering expanded capabilities to clients worldwide.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

NDA Partners competitors and assessment

Company assessment

Direct peers

  • PharmaLex: Global regulatory affairs, pharmacovigilance, and development consulting firm with deep FDA/EMA expertise serving pharma and biotech. Comparable regulatory services portfolio, scaled larger via acquisitions.
  • ProPharma Group: Parent organization of NDA Partners since 2023; provides regulatory sciences, clinical research solutions, pharmacovigilance, and life science consulting globally. Direct overlap in regulatory consulting for pharma, biotech, and medical device clients.
  • Camargo Pharmaceutical Services: Boutique regulatory and drug development consultancy serving emerging and mid-size pharma with 505(b)(2), ANDA, and full development pathway services. Closely comparable in niche positioning and small-firm, expert-led delivery model.
  • Biologics Consulting Group: Specialty regulatory consulting firm staffed largely by former FDA reviewers and industry experts, focused on biologics, cell and gene therapies, and related CMC/regulatory submissions. Comparable expert-network model and FDA alumni bench.
  • The Weinberg Group: Regulatory and scientific consulting firm supporting medical device, pharmaceutical, and combination product companies with FDA strategy, submissions, and quality compliance. Comparable in regulatory advisory focus and mid-size boutique scale.
  • CTI Clinical Trial & Consulting Services: Mid-size CRO with strong regulatory, clinical development, and product strategy consulting for pharma and biotech, including rare disease and biologics. Comparable in regulatory and development program support with a smaller, expert-led footprint.

Broad incumbents

  • ICON plc: Major global CRO providing clinical, regulatory, and consulting services to pharma, biotech, and medical device companies. Overlaps with NDA Partners in regulatory strategy and development consulting at a much larger scale.
  • Charles River Laboratories: Global CRO/preclinical services provider with regulatory and development consulting capabilities supporting pharma and biotech product development. Adjacent but broader in scope, with overlapping regulatory consulting offerings.
  • IQVIA: Largest global CRO with extensive regulatory affairs, R&D consulting, and product development services for life sciences companies. Competes for the same large-pharma and emerging-biotech clients at a different scale.
  • Parexel International: Large global CRO offering regulatory strategy, clinical development, and product development consulting across pharma, biotech, and medical devices. Overlaps with NDA Partners on regulatory advisory but serves a much broader portfolio.

Market position

Strengths5 records

Weaknesses2 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

NDA Partners social profiles

Digital presence

NDA Partners financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NDA Partners leadership team

Management profile

Number of profiles

Profiles15 records

NDA Partners funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NDA Partners M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NDA Partners

What does NDA Partners do?

NDA Partners provides high-value expert consulting services to pharmaceutical, biotechnology, and medical device companies worldwide, covering the full product development life cycle from initial concept through marketing authorization. Core offerings include Expert Advisory Services on regulatory strategy, Product Development Teams (PDTs) that design and manage development programs, and specialized services in biostatistics, market access, pediatrics, quality management systems, and expert witness support for litigation. The firm assigns top-tier Expert Consultants, including former FDA Center Directors and senior industry executives, on every engagement.

Is NDA Partners a public or private company?

NDA Partners is a private company. It is classified as corporate owned and is currently operating.

When was NDA Partners founded?

NDA Partners was founded in 2013. It employs 51 to 100 people.

Where is NDA Partners based?

NDA Partners is headquartered in Washington, United States, in the North America region.

How does NDA Partners make money?

Four revenue lines are on record. Expert Advisory Services are the primary driver. The others are development Teams, specialized Service Offerings and expert Witness Services.

Who are NDA Partners's main competitors?

Direct peers on record are PharmaLex, ProPharma Group, Camargo Pharmaceutical Services, Biologics Consulting Group, The Weinberg Group and CTI Clinical Trial & Consulting Services. Broad incumbents are ICON plc, Charles River Laboratories, IQVIA and Parexel International.

Does NDA Partners have an API?

No public API is recorded for NDA Partners.

What industry is NDA Partners in?

NDA Partners's product category is Life Sciences Consulting. Its primary akta.pro industry code is HLAIALAH, Regulatory Strategy & IND/NDA/BLA Submissions Support, with a secondary code of HLAGAKAI, Clinical Quality Assurance (GCP QA, TMF/QMS oversight). Its NAICS code is 54161 and its SIC code is 8742.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PrwebFormer FDA Reviewer and Investigator, Division of Manufacturing and Product Quality, CBER, Joins NDA Partners as Expert ConsultantJohn Godshalk, a former FDA reviewer and investigator in CBER's Division of Manufacturing and Product Quality, joined NDA Partners as an Expert Consultant. He brings expertise in CMC, quality systems, and cGMP for biologics, including cell and gene therapies. The firm highlighted his experience with BLA submissions and pre-approval inspections.PrwebThe Planet Group Announces Agreement to Acquire NDA Partners, a Life Sciences Management Consulting and Contract Development OrganizationThe Planet Group agreed to acquire NDA Partners, a life sciences management consulting and contract development organization. The acquisition is the fourth in as many years for Planet, which will continue to expand through future M&A activity.PrwebCynthia Koeneman, MBA, Clinical Laboratory Scientist, Joins NDA Partners as Expert ConsultantCynthia Koeneman, a clinical laboratory scientist, joined NDA Partners as an Expert Consultant, announced by Chairman Carl Peck. She brings expertise in clinical laboratory diagnostics, quality assurance, and regulatory compliance, including CAP and CLIA regulations. She previously served as Microbiology Laboratory Manager at Sonora Quest Laboratories.PrwebBiomedical Engineer and Quality Assurance Expert, Jeffrey P. Taub, Joins NDA Partners as Expert ConsultantJeffrey Taub, a biomedical engineer with over 25 years of experience in medical device design and quality assurance, joined NDA Partners as an Expert Consultant. His expertise includes ISO 13485, FDA QSR, risk-based product development, and design controls. He previously held senior roles at Paramit, Surgitech, and Vital Therapies.PrwebFormer FDA Branch Chief of Radiation Programs Joins NDA Partners as Expert ConsultantOrhan H. Suleiman, former FDA Branch Chief of Radiation Programs, joined NDA Partners as an expert consultant. He brings 42 years of experience, including 37 at the FDA, and expertise in health physics and radiology. The firm said his background will be valuable for clients developing radiation products and therapies.PrwebFormer Boehringer Ingelheim Regulatory Affairs and Quality Executive Joins NDA Partners as Expert ConsultantMonika Richter, a senior regulatory affairs and quality executive with over 20 years of experience, joined NDA Partners as an Expert Consultant. She previously held senior roles at Boehringer Ingelheim, including Senior Vice President of Global Regulatory Affairs and Vice President of Global Quality Management Medicine.PrwebInternationally Recognized Healthcare Executive, Diane Jorkasky, MD, FACP, Joins NDA PartnersDiane Jorkasky, MD, FACP, has joined NDA Partners as an Expert Consultant, announced by Chairman Carl Peck. She previously served as executive vice president and chief medical officer at Complexa and held senior roles at Pfizer and SmithKline Beecham. Her expertise spans drug development, clinical pharmacology, and regulatory science.PrwebMarque D. Todd, MS, DVM, DABT, Joins NDA Partners as Regulatory Toxicology ExpertNDA Partners announced that Dr. Marque Todd, a regulatory toxicology expert with over 20 years of industry experience, has joined as an Expert Consultant. She previously served as a Research Fellow at Pfizer and held roles at Amgen and Chiron. Her expertise spans biotherapeutics and oncology, including monoclonal antibodies and CAR-T cells.PrwebSenior Regulatory Affairs and Program Management Executive, Robert Peterson, RAC, Joins NDA PartnersRobert Peterson, a regulatory affairs and program management executive with over 33 years of experience, joined NDA Partners as an Expert Consultant. He previously served as Executive Director of Regulatory Affairs at Liquidia Technologies and held roles at Nephrogenex, Cardiopolymers, and Biostratum. NDA Partners, a life sciences consulting and contract development organization, announced the addition.PrwebSenior Regulatory Affairs Executive, Gregory T. Bates, DVM, Joins NDA Partners as Expert ConsultantGregory T. Bates, DVM, joined NDA Partners as an Expert Consultant, bringing over 30 years of regulatory affairs experience. He currently serves as Senior Vice President of Regulatory Affairs at Axial Biotherapeutics and Regulatory Affairs Lead at ATAI Life Sciences. His expertise covers drugs, biologics, and live biotherapeutic products.